Aussie CSL Signs $1.5 Billion, 5-Year Contract For U.S. Flu Antigens
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL won a maximum $1.5 billion contract from the U.S. government to supply antigens to combat a possible influenza pandemic within the next five years.